Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
Litigation Expenses: $12.5 million accrued in Q3 2024. Research and Development Expenses: $13.5 million for the quarter. Selling, General, and Administrative Expenses: $28.7 million for the quarter. Cash and Investments: $694.2 million in total cash plus short-term and long-term investments at the end of Q3 2024. Total Net VYJUVEK Revenue Since Launch: Over $250 million since August 2023. Warning! GuruFocus has detected 4 Warning Sign with KRYS. Release Date: November 04, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Krystal Biotech Inc ( NASDAQ:KRYS ) reported a significant increase in net VYJUVEK revenue, reaching $83.8 million for the quarter, surpassing $250 million since its launch in August 2023. The company achieved a gross margin of 92%, indicating strong profitability from its operations. Krystal Biotech Inc ( NASDAQ:KRYS ) is on track for a CHMP opinion in Europe before year-end and has secured e
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.MarketBeat
- Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.MarketBeat
- Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung CancerGlobeNewswire
KRYS
Earnings
- 11/4/24 - Beat
KRYS
Sec Filings
- 12/18/24 - Form 8-K
- 12/13/24 - Form 4
- 12/13/24 - Form 4
- KRYS's page on the SEC website